Compound to Control Presbyopia Symptoms
Phase 1
Completed
- Conditions
- Presbyopia
- Registration Number
- NCT05006898
- Lead Sponsor
- Optall Vision
- Brief Summary
Low dose compose to control presbyopia symptoms
- Detailed Description
A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- healthy
- Presbyopic
- 40 - 59 years
Exclusion Criteria
- Diabetics
- Previous eye surgery
- Previous eye disease
- > 0.50 myopia
- > 1.5 hyperopia or astigmatism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Jaeger notation near uncorrected visual acuity change 1 hour Number of lines improved 1 hour after drug instillation
Comparison of PBO compound Jaeger notation improvement vs Pilocarpine or Brimonidine alone 1 hour Number of lines improve comparing PBO compound vs Pilocarpine or Brimonidine
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Optall Vision
🇲🇽Mexico City, Mexico
Optall Vision🇲🇽Mexico City, Mexico